Extended Data Fig. 2: Inhibition of CDC7 induces senescence selectively in liver cancer cells with TP53 mutation.

a, Liver cancer cell lines with TP53 mutation were cultured in the presence of 10 μM XL413 for 4 days, which induces senescence (as detected by SA-β-gal staining). b, Growth curves (measured by Incucyte live-cell analyses) of liver cancer cell lines with TP53 mutations that were either untreated, continuously treated with XL413 or treated with 10 μM of XL413 for 5 or 6 days before withdrawal of treatment. Graphs represent mean ± s.d. from five technical replicates. c, Representative images of H3K9me3 staining in liver cancer cell lines with TP53 mutations, exposed to 10 μM XL413 for 7 days. d, Treatment with XL413 induces a senescence-associated secretory phenotype (SASP) in Hep3B and Huh7 cells treated with 10 μM XL413 for 7 days. mRNA expression of genes associated with the senescence-associated secretory phenotype was determined by qRT–PCR analysis. Graphs represent mean ± s.d. from four technical replicates. e, Liver cancer cells were cultured in the presence of 10 μM XL413 for 4 days, and apoptotic cells were visualized by caspase-3 and caspase-7 apoptosis assay. Data in a are representative of three independent biological experiments. Data in b–e are representative of two independent biological experiments.